Full title:Phase IIb/III clinical trial (SaLuDo, Sarcoma patients treated with
Lurbinectedin and Doxorubicin)) with lurbinectedin in combination with doxorubicin
for the first-line treatment of patients with metastatic Leiomyosarcoma (LMS)
Age: 18+
Phase: 2/3
Locations:
- Birmingham – University Hospital Birmingham NHS Foundation Trust
- London – University College London Hospital (UCLH), The Royal Marsden
- Manchester – The Christie NHS Foundation Trust
Brief summary:
Phase IIb/III clinical trial (SaLuDo, Sarcoma patients treated with Lurbinectedin and Doxorubicin)) with lurbinectedin in combination with doxorubicin for the first-line treatment of patients with metastatic Leiomyosarcoma (LMS). The trial will evaluate Progression-Free Survival (PFS) as the primary endpoint and Overall Survival (OS) as one of the secondary endpoints of treatment with the combination of lurbinectedin and doxorubicin compared to the current standard of care in Leiomyosarcoma, which is doxorubicin.
To find out more about this trial and whether you could take part, talk to your clinical team.
